§ Comparison

GHK-Cu vs Retatrutide

Side-by-side price comparison across every tracked vendor. Updated every 4–6 hours.

GHK-Cu
24
vendors tracked
from $0.27/mg
Retatrutide
14
vendors tracked
from $2.90/mg
◎ Cheapest $/mg:GHK-Cu at $0.27/mg

GHK-Cu

Copper-bound tripeptide for skin + hair

Operational
$27.49
$0.27/mg
In stockOn sale
Buy with code →
Operational
$34.99
$0.35/mg
In stock27.3% vs best
Visit →
Operational
$36.75
$0.37/mg
In stockOn sale33.7% vs best
Visit →
$37.49
$0.37/mg
In stock36.4% vs best
Visit →
Operational
$48.00
$0.48/mg
In stock74.6% vs best
Visit →
Operational
$49.00
$0.49/mg
In stock78.2% vs best
Visit →
$53.00
$0.53/mg
In stock92.8% vs best
Visit →
Operational
$53.00
$0.53/mg
In stock92.8% vs best
Visit →
Operational
$55.00
$0.55/mg
In stock100.1% vs best
Visit →
$55.00
$0.55/mg
In stock100.1% vs best
Visit →
$59.99
$0.60/mg
In stock118.2% vs best
Visit →
$59.99
$0.60/mg
In stock118.2% vs best
Visit →
Operational
$69.00
$0.69/mg
In stock151.0% vs best
Visit →
Operational
$80.00
$0.80/mg
In stockOn sale191.0% vs best
Visit →
$91.79
$0.92/mg
In stock233.9% vs best
Visit →
Operational
$102.99
$1.03/mg
In stock274.6% vs best
Visit →
Sort:
2026-05-04

Retatrutide

Triple GCG/GIP/GLP-1 agonist

Operational
$29.00
$2.90/mg
In stockOn sale
Buy with code →
Operational
$54.50
$5.45/mg
In stock87.9% vs best
Visit →
Operational
$78.00
$7.80/mg
Out of stock169.0% vs best
Visit →
Operational
$79.00
$7.90/mg
In stock172.4% vs best
Visit →
$103.99
$10.40/mg
In stock258.6% vs best
Visit →
Operational
$107.25
$10.72/mg
In stock269.8% vs best
Visit →
Operational
$109.00
$10.90/mg
In stock275.9% vs best
Visit →
$109.00
$10.90/mg
In stock275.9% vs best
Visit →
Operational
$109.99
$11.00/mg
Out of stock279.3% vs best
Visit →
$129.99
$13.00/mg
Out of stock348.2% vs best
Visit →
$188.99
$18.90/mg
In stock551.7% vs best
Visit →
Sort:
2026-05-04

About GHK-Cu

The copper-bound form of GHK, extensively studied for skin renewal, wound healing, and hair follicle signaling.

About Retatrutide

An investigational triple-agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 clinical trials for obesity are ongoing; research-compound version is sold via research-chemical vendors.